Estamos realizando la búsqueda. Por favor, espere...
Abstract: Proliferation signal inhibitors (PSI; sirolimus, everolimus) are being increasingly used in heart transplantation. We performed an observational, retrospective, multicenter study in 9 Spanish centers seeking to describe the clinical context in which a PSI was used among maintenance heart recipients and its evolution over time. We collected a cohort of 548 patients in whom a PSI was prescribed from October 2001 to March 2009. The group was divided into 3 time periods. The use of PSI steeply increased in the 2005-2006 period, remaining stable thereafter. There were no significant differences over time with regard to age, gender, or time from transplantation to the introduction of the PSI. Everolimus usage overtook sirolimus from 2005 on; currently, >90% of the subjects with PSI indications are prescribed everolimus. Compared with earlier periods, patients in the more recent period (October 2006-March 2009) showed less vascular graft disease and better basal renal function, irrespective of the primary indication for the PSI prescription. Also, skin cancer overtook solid cancer as the main type of neoplasm in patients for whom malignancy was the primary indication for the use of the PSI. The actuarial incidence of PSI withdrawal owing to adverse effects did not change significantly over time.
Fuente: Transplantation Proceedings, 2010, 42(8), 2997-3000
Año de publicación: 2010
Nº de páginas: 3
Tipo de publicación: Artículo de Revista
ARIZÓN, J. M.
DELGADO, J. F.
DIEZ DE MOLINA, B.
PANIAGUA, M. J.
JOSE ANTONIO VAZQUEZ DE PRADA TIFFE